Mutations in RASGRP2 gene identified in patients misdiagnosed as Glanzmann thrombasthenia patients.


Journal

Blood cells, molecules & diseases
ISSN: 1096-0961
Titre abrégé: Blood Cells Mol Dis
Pays: United States
ID NLM: 9509932

Informations de publication

Date de publication:
07 2021
Historique:
received: 13 01 2021
revised: 24 02 2021
accepted: 01 03 2021
pubmed: 13 3 2021
medline: 10 8 2021
entrez: 12 3 2021
Statut: ppublish

Résumé

Glanzmann thrombasthenia (GT) is a severe inherited platelet function disorder (IPFD), presenting with bleeding diathesis and impaired platelet aggregation, is caused by mutations in the genes ITGA2B or ITGB3. We aimed to study the genetic cause of IPFD mimicking GT. During 2017-2019, 16 patients were referred to our tertiary center with bleeding symptoms, impaired platelet aggregation and normal platelet count and size. Using flow cytometry, 13/16 patients were diagnosed with GT, yet three patients displayed normal surface expression of the integrins αIIbβ3 and αvβ3, as well as normal integrin αIIbβ3 activation following incubation with the activating monoclonal antibody anti-LIBS6, while platelet activation following ADP or epinephrine was impaired. Whole exome sequencing detected 2 variants in RASGRP2 gene in all 3 patients. Both RASGRP2 mutations predicted frameshift, premature stop codon (p. I427Mfs*92 and p. R494Afs*54, respectively) and truncated calcium-sensing guanine nucleotide exchange factor [CalDAG-GEFI]- the major signaling molecule that regulates integrin-mediated aggregation and granule secretion, causing IPFD-18. Patients who suffer from bleeding diathesis without immune dysregulation, may be mistakenly diagnosed as GT. Further studies are required to confirm the diagnosis of specific IPFD.

Identifiants

pubmed: 33711653
pii: S1079-9796(21)00026-7
doi: 10.1016/j.bcmd.2021.102560
pii:
doi:

Substances chimiques

Guanine Nucleotide Exchange Factors 0
RASGRP2 protein, human 0

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

102560

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

Nurit Rosenberg (N)

The Israeli National Hemophilia Center and Thrombosis Institute, Sheba Medical Center, Tel Hashomer, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; Amalia Biron Research Institute of Thrombosis and Hemostasis, Sheba Medical Center, Tel Hashomer, and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Rima Dardik (R)

The Israeli National Hemophilia Center and Thrombosis Institute, Sheba Medical Center, Tel Hashomer, Israel.

Hagit Hauschner (H)

The Israeli National Hemophilia Center and Thrombosis Institute, Sheba Medical Center, Tel Hashomer, Israel; Amalia Biron Research Institute of Thrombosis and Hemostasis, Sheba Medical Center, Tel Hashomer, and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Sigal Nakav (S)

Coagulation and Hemostasis Laboratory, Hematology Laboratories, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel.

Ortal Barel (O)

Bioinformatic Unit, Sheba Cancer Research Center, Tel-Hashomer, Israel.

Jacob Luboshitz (J)

The Israeli National Hemophilia Center and Thrombosis Institute, Sheba Medical Center, Tel Hashomer, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Joanne Yacobovich (J)

Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; Pediatric Hematology, Schneider Children's Medical Center, Petach-Tikva; Israel.

Hannah Tamary (H)

Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; Pediatric Hematology, Schneider Children's Medical Center, Petach-Tikva; Israel.

Gili Kenet (G)

The Israeli National Hemophilia Center and Thrombosis Institute, Sheba Medical Center, Tel Hashomer, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; Amalia Biron Research Institute of Thrombosis and Hemostasis, Sheba Medical Center, Tel Hashomer, and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: gili.kenet@sheba.health.gov.il.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH